PMCC: Ranked 2nd in the world for % of research papersNot bad, as a partner! ... ;-)
2nd IN THE WORLD Ranked 2nd in the world for percentage of research papers published in high-impact oncology journals Source: PMCC 2018 Annual Report
___________________
Claridge - (6/13/2019 8:27:07 PM) RE:10 presentations on TLT's scientific platform in 10 days Some of the 10 upcoming presentations:
Friday 28 June 2019
Current clinical translation of PDT
Paper 11070-705
Time: 3:20 PM - 4:00 PM
Author(s): Lothar D. Lilge, Princess Margaret Cancer Ctr. (Canada)
Abstract: We will review approved photosensitizers in various jurisdictions including the indication for which they are approved and possible of label use of these photosensitizers. We review previous clinical trials which failed, focusing in particular on what lead to failures in some clinical trial. We discuss the need to have a physicist involved in the treatment planning and possibly even his presence during PDT delivery. Topics addressed: – Approved Photosensitizers and current clinical trials. – Failures of previous clinical trials – A physicist in the OR (operating room) Session 4: PDT in the Brain Sunday 30 June 2019 Efficacy of ruthenium coordination complex based Rutherrin in a pre-clinical rat glioblastoma (GBM) model Paper 11070-26 Time: 12:00 PM - 12:15 PM Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Manjunatha Ankathatti Munegowda, Theralase Technologies, Inc. (Canada); Carl Fisher, Univ. Health Network (Canada); Arkady Mandel, Theralase Technologies, Inc. (Canada) Abstract: The efficacy of Rutherrin based on the Photosensitizer TLD1433 was evaluated in the RG2 preclinical glioma model in vitro and in vivo. The in vitro LD50 as a function ofphotons absorbed by the photosensitizer was lower than for ALA-induced PpIX using previously published protocols. In vivo Rutherrin demonstrated a higher specific uptake ratio, longer survival times, lower edema and a higher infiltration of CD8+T immune-regulating cells and the in vivo threshold (number of photons absorbed to cause cell death) is two orders of magnitude lower compared to ALA-induced PpIX treated animals.
Sunday 30 June 2019
Session Chairs: Henri Azas, Piti-Salptrire Hospital (France)
TLD-1433 photodynamic therapy for BCG-unresponsive NMIBC: a Phase IB clinical study (Invited Paper) Paper 11070-51 Time: 2:50 PM - 3:10 PM Author(s): Lothar D. Lilge, Univ. Health Network (Canada), Univ. of Toronto (Canada); Girish Kulkani, Univ. of Toronto (Canada), Univ. Health Network (Canada); Arkady Mandel, Theralase, Inc. (Canada); Nathan Perlis, Michael Nesbitt, Univ. Health Network (Canada); Roger White , Wayne Embree , Theralase, Inc. (Canada); Michael Jewett , Univ. of Toronto (Canada) Abstract: TDL1433 mediated PDT for NMIBC for patients who failed standard BCG immunotherapy was shown to be safe and well tolerated at the therapeutic dose. Contributing to the safety of the treatment is instilling the PS to minimize pharmacokinetic influences on the drug dose, and monitoring the irradiance on the bladder wall to minimize optical effects when illuminating a cavity with unknown optical properties. Light source limitations resulted in long irradiation times, and higher total power fiber optical delivery must be attained for clinical translation. The exploratory efficacy data is encouraging. Session 16: Does PDT have a Role in Vaccine Development? Monday 1 July 2019 A new platform technology RuVaCare, an extracorporeal anti-cancer vaccine is efficient in breaking immune barrier to target cancer cells Paper 11070-110 Time: 6:00 PM - 6:15 PM Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Manjunatha Ankathatti Munegowda, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Roger Dumoulin-White, Theralase Technologies, Inc. (Canada) Abstract: A stronger anti-tumour immune response is essential to overcome the immune suppressive mechanisms adopted by cancers. We have evaluated a whole cell vaccine with extracorporeal Rutherrin®-PDT treated cancer cells (RuVaCareTM) to break the suppressive barrier in an aggressive RG2-glioblastoma model. RuVaCare™ induced immunogenic cell death (ICD), induced immunostimulatory cytokines (IFNa, IL-1b, GMCSF), increased the survival of vaccinated rats and induced CD8+T cell responses. RuVaCare ™ may simultaneously target multiple tumor antigens to activate the T-cell mediated immune response to fight cancer and/or prevent the recurrence of the disease, which is of highest clinical value and scientific interest. Session 22: Image-Guided Optimization and Prediction for Effective Photodynamic Therapy Dosimetry recommendations for NMIBC: a simulation and in vivo study Paper 11070-146 Time: 12:15 PM - 12:30 PM Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Daniel Molehuis, Univ. of Toronto (Canada); Angelica Manalac, McMaster Univ. (Canada); Fynn Schwiegelshohn, Ruhr-Univ. Bochum (Germany); Vaughn Betz, Univ. of Toronto (Canada); Wayne Embree, Arkady Mandel, Roger Dumoulin-White, Theralase Technologies, Inc. (Canada); Girish Kulkani, Michael Jewett, Univ. Health Network (Canada) Abstract: Optimizing and monitoring the irradiance of a bladder wall was investigated throughnumerical simulations of 6 anatomical bladders as a function of the average tissue optical properties. To quantify the average bladder wall irradiance, multiple sensors are required to become independent of the bladder shape. Nevertheless, the sensor’s responsivity to any given irradiance at the bladder wall remains slightly dependent on the tissue optical properties as well as those of the bladder void if the latter cannot be kept transparent. The experimentally measured irradiances ranges in each bladder matched those predicted by the simulations for the first six patients in a clinical trial of TLD1433 mediated Photodynamic Therapy. Session 23: Dosimetry and Interstitial PDT Modelling novel PDT approaches to target peripheral lung cancers Paper 11070-150 Time: 11:30 AM - 11:45 AM Author(s): Lothar D. Lilge, Univ. Health Network (Canada); Christopher McFadden, Univ. of Toronto (Canada); Khaled Ramadan, Univ. Health Network (Canada); Zhangcheng Zheng, Univ. of Toronto (Canada); Fynn Schwiegelshohn, Ruhr-Univ. Bochum (Germany); Vaughn Betz, Univ. of Toronto (Canada); Marcelo Cypel, Univ. Health Network (Canada) Abstract: In silico simulations highlight the ability and limitations to target peripheral lung tumours either as an index lesion or as diffuse disease throughout one lobe. Using estimated PDT tissue Threshold values from literature and measured tissue optical properties the simulations provide required photosensitizer selective uptake ratios to achieve more than 98% tumour destruction at the established clinically acceptable extent of normal lung tissue damage. Hence, using this tool, the oncological surgeon can evaluate for each patient if and how transbronchial PDT can be a promising treatment modality.